CREATE ACCOUNT

Request Registration Code

Terms of Service

All messages posted at this site express the views of the author, and do not necessarily reflect the views of the owners and administrators of this site.

By registering at this site you agree not to post any messages that are obscene, vulgar, slanderous, hateful, threatening, or that violate any laws. We will permanently ban all users who do so.

We reserve the right to remove, edit, or move any messages for any reason.

  I agree to the terms of service

FORGOT YOUR DETAILS?

2021 Annual General Meeting

Monday, 12 July 2021 by System Administrator

Ci exterior800

2021 Cryonics Institute Annual General Meeting
SUNDAY - SEPT 12, 2021

AGM Location:
Infinity Hall & Sidebar
16650 E 14 Mile Road
Fraser, MI 48026
phone: 586-879-6157
website: infinityhallsidebar.com

2021 AGM Details
Sunday, September 12, 2021
Event start time: 3:00 pm
Event end time: 6:30 pm

Facility Tours
Tours of the Main and new Ancillary Facilities will be conducted from 1:00 p.m. to 2:30 p.m. at 24355 Sorrentino Court, Clinton Township, MI.
* Doors open at approximately 12:30 pm. Note the facility is not open to guests prior to this time, so please do not arrive early to visit with staff as we will be preparing for the tours and the meeting.

Night Before Dinner
For those who come a day early, a get together will be held at 6 pm on Saturday evening at Sajo’s Restaurant. 36470 Moravian, Clinton Twp., MI 48035. Phone: (586) 792-7256. www.Sajos.net.

ZOOM Virtual Meeting
CI will be live-streaming the meeting on Zoom. Please see our website on or around August 1 for the specific link and more details.

Using Virtual popuations for clinical trials

Thursday, 24 June 2021 by System Administrator

Fotolia 56817712 xs


A study involving virtual rather than real patients was as effective as traditional clinical trials in evaluating a medical device used to treat brain aneurysms, according to new research.

The findings are proof of concept for what are called in-silico trials, where instead of recruiting people to a real-life clinical trial, researchers build digital simulations of patient groups, loosely akin to the way virtual populations are built in The Sims computer game.

In-silico trials could revolutionise the way clinical trials are conducted, reducing the time and costs of getting new medical devices and medicines developed, while reducing human and animal harm in testing.

The virtual patient populations are developed from clinical databases to reflect age, sex and ethnicity but they also simulate the way disease affects the human body: for example, the interactions between anatomy, physics, physiology, and blood biochemistry. Those simulations are then used to model the impact of therapies and interventions.

The international research, led by the University of Leeds and reported today (23 June) in the journal Nature Communications, investigated whether an in-silico trial could replicate the results of three, real-life clinical trials that assessed the effectiveness of a device called a flow diverter, used in the treatment of brain aneurysms, a disease where the wall of a blood vessel weakens and begins to bulge.

Flow diverter reduces blood flow into the aneurysm

A flow diverter is a small, flexible mesh tube which is guided to the site of the aneurysm by a doctor using a catheter. Once in place, the flow diverter directs blood along the blood vessel and reduces flow into the aneurysm, initiating a clotting process that eventually cuts the aneurysm off from blood circulation, thus healing it.

Without successful treatment, the aneurysm can burst causing a bleed on the brain and a stroke.

To establish their proof of concept, the researchers had to see if the results from their in-silico study agreed with the results from three previous major clinical trials into the effectiveness of flow diverters.

The 'participants' in the virtual trial

The researchers built a virtual population using real patient data drawn from clinical databases, ensuring that the anonymised virtual patients closely resembled the patients used in real flow diverter clinical trials in terms of age, sex and aneurysm characteristics.

The researchers then built a computational model that analysed how the implanted device would affect blood flow in each of the virtual patients. They were able to study different physiological conditions for each patient, such as normal and high blood pressure, and perform analyses on patient sub-groups, such as those with large aneurysms or aneurysms with a branch vessel.

The in-silico trial had 82 virtual cases.

The traditional clinical trials (called PUFS, PREMIER and ASPIRe) had 109,141 and 207 patients, respectively. Around half the cases in the traditional trials had high blood pressure.

The results of the in-silico trial predicted that 82.9% of the virtual patients with normal blood pressure would be successfully treated with a flow diverter. In the traditional clinical trials, the number of people who were successfully treated was 86.8%, 74.8% and 76.8%, respectively, thus showing that the in-silico trial replicated the traditional clinical trials results.

In-silico trials generate 'huge benefits'

Professor Alex Frangi, Diamond Jubilee Chair in Computational Medicine and Royal Academy of Engineering Chair in Emerging Technologies at the University of Leeds, who supervised the study, said: "The results demonstrate the huge potential of in-silico trials. We have shown that the approach can replicate the findings of traditional clinical trials -- and they do that in a fraction of the time it normally takes, and at a fraction of the cost."

In the in-silico trial, the researchers were also able to adapt their computational model to investigate new hunches or emerging scientific findings.

By modelling the physics of blood flow and the biochemistry of blood clotting in aneurysms under different physiological conditions, they were able to identify sub-groups of patients at higher risk of stroke, with patients with large complex-shaped aneurysms at higher risk of haemorrhagic stroke and patients with hypertension at higher risk of ischaemic stroke.

Being able to rigorously analyse medical device performance in this way will allow biomedical engineers to optimise the device design and reduce the risks associated with treatment.

Clinical trials 'cut from years to months'

Professor Frangi said: "In-silico trials offer an opportunity to do virtual experiments that could explain concepts that are difficult to study in conventional clinical trials.

"The current approach to improve our understanding of new medical devices is slow, as conventional trials can easily take five to eight years, from their design to completion.

"In-silico trials could reduce this period to less than six months in some circumstances, making knowledge and therapeutic technologies safer and more promptly available to clinicians and patients."

The research involved an international collaboration of scientists from Leeds, the University of Oxford, Radbound University Medical Centre in the Netherlands, and KU Leuven in Belgium.

The research was funded through the Royal Academy of Engineering (INSILEX), @neurIST from the European Commission and the Engineering and Physical Sciences Research Council Centre for Doctoral Training on Fluid Dynamics.

 

Story Source:

Materials provided by University of Leeds. Note: Content may be edited for style and length.


Journal Reference:

  1. Ali Sarrami-Foroushani, Toni Lassila, Michael MacRaild, Joshua Asquith, Kit C. B. Roes, James V. Byrne, Alejandro F. Frangi. In-silico trial of intracranial flow diverters replicates and expands insights from conventional clinical trials. Nature Communications, 2021; 12 (1) DOI: 10.1038/s41467-021-23998-w

Cite This Page:

University of Leeds. "Using virtual populations for clinical trials." ScienceDaily. ScienceDaily, 23 June 2021. <www.sciencedaily.com/releases/2021/06/210623091139.htm>.

U.S. Report Found It Plausible Covid-19 Leaked From Wuhan Lab

Thursday, 24 June 2021 by System Administrator

Fotolia 79616232 xs

WASHINGTON—A report on the origins of Covid-19 by a U.S. government national laboratory concluded that the hypothesis claiming the virus leaked from a Chinese lab in Wuhan is plausible and deserves further investigation, according to people familiar with the classified document.

The study was prepared in May 2020 by the Lawrence Livermore National Laboratory in California and was drawn on by the State Department when it conducted an inquiry into the pandemic’s origins during the final months of the Trump administration.

It is attracting fresh interest in Congress now that President Biden has ordered that U.S. intelligence agencies report to him within weeks on how the virus emerged. Mr. Biden said that U.S. intelligence has focused on two scenarios—whether the coronavirus came from human contact with an infected animal or from a laboratory accident.

People familiar with the study said that it was prepared by Lawrence Livermore’s “Z Division,” which is its intelligence arm. Lawrence Livermore has considerable expertise on biological issues. Its assessment drew on genomic analysis of the SARS-COV-2 virus, which causes Covid-19, they said.

TOP